ClinicalTrialsFinder

Resectable Hepatocellular Carcinoma With High Risk of Recurrence Clinical Trials in Shenyang, Liaoning

1 recruitingShenyang, Liaoning, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences30 enrolled4 locationsNCT07239245